Drugs that target this pathway have been clinically validated in patient subgroups, such as the use of PARP (poly ADP-ribose polymerase) inhibitors to treat BRCA1/BRCA2 mutant breast cancer patients [40]. Here, BRCA2 is linked to breast cancer.